| abstract |
The invention relates to a compound having formula (I) or a stereoisomer, a salt or a solvate, in which: A is -CH(OH)- or -C(=0)-; Z is H or OH; n is 0 or 1; R 1 is alkyl(C 1 -C 30 ), alkenyl(C 2 -C 30 ) or alkynyl(C 2 -C 30 ); B is -H, -N 3 or -CΞCH; R 2 is -NHR 3 or maleimide; R 3 is -COR 4 , -COCOR 4 or -SO 2 R 4 ; and R 4 is alkyl(C 1 -C 16 ), alkenyl(C 2 -C 16 ), alkynyl(C 2 -C 16 ), epoxide or aziridine, on the condition that: a) when A is -CH(OH) and B is H, R 3 is different from -COR 4 , R 4 being alkyl(C 1 -C 16 ); b) when A is -CH(OH), B is H and R 3 is -COCOR 4 , R 4 being alkyl(C 6 ), R 1 is different from -CH=CH 2 -alkyl(C 12 ), -CΞCH-alkyl(C 12 ) or alkyl(C 13 -C 15 ); or c) when A is -C(=O), R 1 is alkenyl(C 2 -C 30 ), B is H and n is 0, R 3 is different from -COR 4 , R 4 being alkyl(C 1 C 16 ). The invention also relates to the use of the compound having formula (I), 2,2-dibromo-N-((2S,3R)-1,3-dihydroxyoctadecan-2-il)acetamide or 2-bromo-N-((2S,3R)-1,3-dihydroxyoctadecan-2-il)acetamide in the treatment or prevention of a disease associated with cellular hyperproliferation, either alone or in combination. |